Items Tagged ‘durvalumab’

June 22nd, 2017

Immunotherapy with Checkpoint Inhibitor Durvalumab Show Promise in Triple Negative Breast Cancer

By

Doctors from Yale Cancer Center presented new data at the American Society of Clinical Oncology meeting on the impact of combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer (TNBC).  Overall patients with TNBC achieved a 71% pathologic complete response to the combination treatment in the […]

View full entry

Tags: Breast Cancer, checkpoint inhibitor, durvalumab, immunotherapy, News, precision medicine, Triple Negative Breast Cancer


May 30th, 2017

Imfinzi Improves Outcomes for Patients With Stage III Non Small Cell Lung Cancer

By

Positive results for the PACIFIC clinical trial evaluating the novel precision medicine, Imfinzi (durvalumab) as sequential treatment in patients with Stage III non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy have been reported.1 Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, […]

View full entry

Tags: durvalumab, Imfinzi, Lung Cancer - Non-Small Cell, News, nsclc, precision medicine, Stage III non-small cell lung cancer


May 11th, 2017

FDA Approves Imfinzi for Treatment of Urothelial Cancer

By

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of treatment with that chemotherapy. Bladder cancer is the most common type […]

View full entry

Tags: Bladder Cancer, durvalumab, Imfinzi, immunotherapy, News, PD-1, urothelial carcinoma